The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
BeiGene, a Beijing-based bio/pharmaceutical company, has entered into a purchase agreement to acquire an approximately 42-acre site to build a new campus for R&D and manufacturing in Hopewell, New Jersey.
The 42-acre site provides over one...
Amgen has announced plans to invest $550 million to build a new multi-product biologic drug-substance manufacturing facility in Holly Springs, North Carolina.
The new plant will support traditional stainless-steel-fed batch manufacturing and...
The latest on COVID-19 vaccines/drugs and manufacturing from Pfizer, Moderna, AstraZeneca, J&J, Emergent BioSolutions, Sanofi, GSK, Vir Biotechnology, BI, Sinovac, and others.
Manufacturing and supply of COVID-19 vaccines and drugs
Pfizer,...
A bipartisan group of members of the US House of Representatives sent a letter to the US Food and Drug Administration (FDA) asking for additional information about the impact COVID-19 has had on inspections of drug-manufacturing facilities and what...
A roundup of news from Africa (BioNTech), China (Merck KGaA) and the US (AstraZeneca, Regeneron, Viatris, Takeda, BlueRock Therapeutics, and others).
Africa
BioNTech in Project for mRNA Malaria Vaccine; Evaluates Mfg in AfricaBioNTech, a Mainz,...
Bayer has set aside an additional $4.5 billion to address potential claims over its glyphosate-based herbicide, Roundup, and updated a plan for closing litigation. The company provided an update on its five-point plan to address future litigation...
GlaxoSmithKline (GSK) has appointed Brian McNamara, the CEO of GSK Consumer Healthcare, a joint venture between GSK and Pfizer, as CEO Designate of a new, to-be-listed Consumer Healthcare company that will result from the proposed demerger of the...
Amgen has agreed to acquire Teneobio, a Newark, California-based clinical-stage bio/pharmaceutical company developing human heavy-chain antibodies, in a deal worth up to $2.5 billion ($900 million upfront and up to an additional $1.6 billion in...
Regeneron Pharmaceuticals, a Tarrytown, New York-based bio/pharmaceutical company, plans to invest approximately $1.8 billion over six years to expand its research, preclinical manufacturing, and support facilities at its headquarters in Tarrytown,...
A roundup of news from Australia (J&J), Germany (Merck KGaA, MorphoSys), Japan (Meiji, Dong-A ST, Intas Pharmaceuticals), and the US (J&J, Kyria Therapeutics).
Australia
J&J Extends Innovation Partnering Office in Australia Johnson...
The latest on COVID-19 vaccines/drugs and manufacturing from Moderna, Pfizer, Roche, Takeda, Regeneron Pharmaceuticals, and Sinovac.
Manufacturing and supply of COVID-19 vaccines and drugs
Takeda, Japan Gov’t Expand Supply Pact for Moderna’s...
In another recall of products in the industry relating to nitrosamine impurities, Pfizer is voluntarily recalling 12 lots of its smoking-cessation product, Chantix (varenicline). This marks the latest product in the industry recalled/investigated...
GlaxoSmithKline (GSK) is seeking to sell 33 acres of land from its R&D campus in Stevenage, UK to a private developer for a proposed life-science campus for biotechnology and early-stage life science companies as part of a plan envisioned by...
BioNTech, a Mainz, Germany-based immunotherapy company, has entered into a purchase agreement with Kite, part of Gilead Sciences, to acquire its solid-tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in...
AstraZeneca has completed its $39-billion acquisition of Alexion Pharmaceuticals, a Boston-based bio/pharmaceutical company focused on rare diseases. The companies had announced the deal in December 2020.
The acquisition marks AstraZeneca’s entry...
